Janine Doesch1, Dirk Debus2, Christian Meyer3, Thomas Papadopoulos3, Erwin S Schultz2, Joachim H Ficker1, Wolfgang M Brueckl4. 1. Department of Respiratory Medicine, Allergology and Sleep Medicine, Paracelsus Medical University, General Hospital Nuernberg, Nuremberg, Germany. 2. Department of Dermatology, Paracelsus Medical University, General Hospital Nuernberg, Nuremberg, Germany. 3. Institute of Pathology, Paracelsus Medical University, General Hospital Nuernberg, Nuremberg, Germany. 4. Department of Respiratory Medicine, Allergology and Sleep Medicine, Paracelsus Medical University, General Hospital Nuernberg, Nuremberg, Germany. Electronic address: Wolfgang.brueckl@klinikum-nuernberg.de.
Abstract
INTRODUCTION: Afatinib is a tyrosine kinase inhibitor (TKI), that has been approved for treating patients with epidermal growth factor receptor (EGFR) mutated advanced non-small-cell lung cancer (NSCLC). Stevens-Johnson syndrome (SJS) related to EGFR directed TKIs is a rare adverse event. CASE PRESENTATION: We report a case of a 79-year-old white female with EGFR-mutated, metastatic non-small-cell lung cancer treated with afatinib as first-line palliative treatment, who developed a SJS after two months of treatment. Discontinuation of the TKI and systemic glucocorticoid treatment led to improvement of symptoms and recovery. CONCLUSION: Severe adverse cutaneous drug reactions that predominantly involve the skin and mucous membranes during treatment with afatinib should alert clinicians to suspect SJS and react appropriately.
INTRODUCTION:Afatinib is a tyrosine kinase inhibitor (TKI), that has been approved for treating patients with epidermal growth factor receptor (EGFR) mutated advanced non-small-cell lung cancer (NSCLC). Stevens-Johnson syndrome (SJS) related to EGFR directed TKIs is a rare adverse event. CASE PRESENTATION: We report a case of a 79-year-old white female with EGFR-mutated, metastatic non-small-cell lung cancer treated with afatinib as first-line palliative treatment, who developed a SJS after two months of treatment. Discontinuation of the TKI and systemic glucocorticoid treatment led to improvement of symptoms and recovery. CONCLUSION: Severe adverse cutaneous drug reactions that predominantly involve the skin and mucous membranes during treatment with afatinib should alert clinicians to suspect SJS and react appropriately.
Authors: Noel Frey; Michael Bodmer; Andreas Bircher; Susan S Jick; Christoph R Meier; Julia Spoendlin Journal: Drug Saf Date: 2019-01 Impact factor: 5.606
Authors: J Wu; D Liu; M Offin; B T Li; M E Lacouture; C Lezcano; J M Torrisi; S Brownstein; D M Hyman; M M Gounder; W Abida; A Drilon; J J Harding; R J Sullivan; F Janku; D Welsch; M Varterasian; A Groover Journal: Invest New Drugs Date: 2021-01-03 Impact factor: 3.651
Authors: E C Kuijper; L E French; C P Tensen; M H Vermeer; J N Bouwes Bavinck Journal: J Eur Acad Dermatol Venereol Date: 2020-05-15 Impact factor: 6.166